Review



monitoring by electrocardiography ecg telemetry  (Philips Healthcare)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Philips Healthcare monitoring by electrocardiography ecg telemetry
    The Dexmedetomidine Trial was conducted at Stanford University’s Clinical and Translational Research Unit (CTRU), while the ACX-02 Clinical Trial was conducted at both Stanford University’s CTRU and Washington State University’s Sleep and Performance Research Center. Both trials used a cross-over design - treatment followed by placebo - to assess the effect of DEX on the glymphatic clearance of Aβ and tau from the brain to the blood. (A) The Dexmedetomidine Trial enrolled nine participants, of whom eight completed both study visits. (B) The ACX-02 Trial enrolled 22 participants, eight at Stanford University and 14 at Washington State University. Of the eight participants at Stanford, six completed both study visits. At Washington State University, 11 of 14 participants completed both study visits. (C) Illustration of the determinants of glymphatic clearance of Aβ and tau during wake, NREM sleep, DEX and ACX-02 treatment. To capture these physiological determinants, participants were instrumented with <t>ECG</t> telemetry, percutaneous oxygen saturation (SpO₂), nasal cannula for low-flow oxygen and continuous end-tidal CO₂ (EtCO₂) monitoring, and a radial arterial line for continuous blood pressure monitoring and blood sampling (Philips IntelliVue MP50). An intravenous line was placed for drug or saline placebo infusion. Participants were also fitted with an investigational in-ear wearable device from Applied Cognition¹⁷ that measured key determinants of glymphatic function, including sleep features (hypnogram and spectral band power) by EEG, heart rate variability (HRV) by photoplethysmography (PPG), cerebrovascular pulse transit time (PTT cereb ) by impedance plethysmography (IPG), and brain parenchymal resistance (R P ) by dynamic electrical impedance spectroscopy.
    Monitoring By Electrocardiography Ecg Telemetry, supplied by Philips Healthcare, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monitoring+by+electrocardiography+ecg+telemetry/6+alice+diagnostic+sleep+system/med_rxiv__64898__2026__03__10__26348048-44-4-57
    Average 86 stars, based on 1 article reviews
    monitoring by electrocardiography ecg telemetry - by Bioz Stars, 2026-08
    86/100 stars

    Images

    1) Product Images from "Pharmacological enhancement of glymphatic function in humans increases the clearance of Alzheimer’s disease-related proteins"

    Article Title: Pharmacological enhancement of glymphatic function in humans increases the clearance of Alzheimer’s disease-related proteins

    Journal: medRxiv

    doi: 10.64898/2026.03.10.26348048

    The Dexmedetomidine Trial was conducted at Stanford University’s Clinical and Translational Research Unit (CTRU), while the ACX-02 Clinical Trial was conducted at both Stanford University’s CTRU and Washington State University’s Sleep and Performance Research Center. Both trials used a cross-over design - treatment followed by placebo - to assess the effect of DEX on the glymphatic clearance of Aβ and tau from the brain to the blood. (A) The Dexmedetomidine Trial enrolled nine participants, of whom eight completed both study visits. (B) The ACX-02 Trial enrolled 22 participants, eight at Stanford University and 14 at Washington State University. Of the eight participants at Stanford, six completed both study visits. At Washington State University, 11 of 14 participants completed both study visits. (C) Illustration of the determinants of glymphatic clearance of Aβ and tau during wake, NREM sleep, DEX and ACX-02 treatment. To capture these physiological determinants, participants were instrumented with ECG telemetry, percutaneous oxygen saturation (SpO₂), nasal cannula for low-flow oxygen and continuous end-tidal CO₂ (EtCO₂) monitoring, and a radial arterial line for continuous blood pressure monitoring and blood sampling (Philips IntelliVue MP50). An intravenous line was placed for drug or saline placebo infusion. Participants were also fitted with an investigational in-ear wearable device from Applied Cognition¹⁷ that measured key determinants of glymphatic function, including sleep features (hypnogram and spectral band power) by EEG, heart rate variability (HRV) by photoplethysmography (PPG), cerebrovascular pulse transit time (PTT cereb ) by impedance plethysmography (IPG), and brain parenchymal resistance (R P ) by dynamic electrical impedance spectroscopy.
    Figure Legend Snippet: The Dexmedetomidine Trial was conducted at Stanford University’s Clinical and Translational Research Unit (CTRU), while the ACX-02 Clinical Trial was conducted at both Stanford University’s CTRU and Washington State University’s Sleep and Performance Research Center. Both trials used a cross-over design - treatment followed by placebo - to assess the effect of DEX on the glymphatic clearance of Aβ and tau from the brain to the blood. (A) The Dexmedetomidine Trial enrolled nine participants, of whom eight completed both study visits. (B) The ACX-02 Trial enrolled 22 participants, eight at Stanford University and 14 at Washington State University. Of the eight participants at Stanford, six completed both study visits. At Washington State University, 11 of 14 participants completed both study visits. (C) Illustration of the determinants of glymphatic clearance of Aβ and tau during wake, NREM sleep, DEX and ACX-02 treatment. To capture these physiological determinants, participants were instrumented with ECG telemetry, percutaneous oxygen saturation (SpO₂), nasal cannula for low-flow oxygen and continuous end-tidal CO₂ (EtCO₂) monitoring, and a radial arterial line for continuous blood pressure monitoring and blood sampling (Philips IntelliVue MP50). An intravenous line was placed for drug or saline placebo infusion. Participants were also fitted with an investigational in-ear wearable device from Applied Cognition¹⁷ that measured key determinants of glymphatic function, including sleep features (hypnogram and spectral band power) by EEG, heart rate variability (HRV) by photoplethysmography (PPG), cerebrovascular pulse transit time (PTT cereb ) by impedance plethysmography (IPG), and brain parenchymal resistance (R P ) by dynamic electrical impedance spectroscopy.

    Techniques Used: Clinical Proteomics, Sampling, Saline, Impedance Spectroscopy



    Similar Products

    monitoring by electrocardiography ecg telemetry  (Philips Healthcare)
    86
    Philips Healthcare monitoring by electrocardiography ecg telemetry
    The Dexmedetomidine Trial was conducted at Stanford University’s Clinical and Translational Research Unit (CTRU), while the ACX-02 Clinical Trial was conducted at both Stanford University’s CTRU and Washington State University’s Sleep and Performance Research Center. Both trials used a cross-over design - treatment followed by placebo - to assess the effect of DEX on the glymphatic clearance of Aβ and tau from the brain to the blood. (A) The Dexmedetomidine Trial enrolled nine participants, of whom eight completed both study visits. (B) The ACX-02 Trial enrolled 22 participants, eight at Stanford University and 14 at Washington State University. Of the eight participants at Stanford, six completed both study visits. At Washington State University, 11 of 14 participants completed both study visits. (C) Illustration of the determinants of glymphatic clearance of Aβ and tau during wake, NREM sleep, DEX and ACX-02 treatment. To capture these physiological determinants, participants were instrumented with <t>ECG</t> telemetry, percutaneous oxygen saturation (SpO₂), nasal cannula for low-flow oxygen and continuous end-tidal CO₂ (EtCO₂) monitoring, and a radial arterial line for continuous blood pressure monitoring and blood sampling (Philips IntelliVue MP50). An intravenous line was placed for drug or saline placebo infusion. Participants were also fitted with an investigational in-ear wearable device from Applied Cognition¹⁷ that measured key determinants of glymphatic function, including sleep features (hypnogram and spectral band power) by EEG, heart rate variability (HRV) by photoplethysmography (PPG), cerebrovascular pulse transit time (PTT cereb ) by impedance plethysmography (IPG), and brain parenchymal resistance (R P ) by dynamic electrical impedance spectroscopy.
    Monitoring By Electrocardiography Ecg Telemetry, supplied by Philips Healthcare, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monitoring+by+electrocardiography+ecg+telemetry/6+alice+diagnostic+sleep+system/med_rxiv__64898__2026__03__10__26348048-44-4-57
    Average 86 stars, based on 1 article reviews
    monitoring by electrocardiography ecg telemetry - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier
    wearable telemetry electrocardiography (ecg) monitor  (Welch Allyn Inc)
    90
    Welch Allyn Inc wearable telemetry electrocardiography (ecg) monitor
    The Dexmedetomidine Trial was conducted at Stanford University’s Clinical and Translational Research Unit (CTRU), while the ACX-02 Clinical Trial was conducted at both Stanford University’s CTRU and Washington State University’s Sleep and Performance Research Center. Both trials used a cross-over design - treatment followed by placebo - to assess the effect of DEX on the glymphatic clearance of Aβ and tau from the brain to the blood. (A) The Dexmedetomidine Trial enrolled nine participants, of whom eight completed both study visits. (B) The ACX-02 Trial enrolled 22 participants, eight at Stanford University and 14 at Washington State University. Of the eight participants at Stanford, six completed both study visits. At Washington State University, 11 of 14 participants completed both study visits. (C) Illustration of the determinants of glymphatic clearance of Aβ and tau during wake, NREM sleep, DEX and ACX-02 treatment. To capture these physiological determinants, participants were instrumented with <t>ECG</t> telemetry, percutaneous oxygen saturation (SpO₂), nasal cannula for low-flow oxygen and continuous end-tidal CO₂ (EtCO₂) monitoring, and a radial arterial line for continuous blood pressure monitoring and blood sampling (Philips IntelliVue MP50). An intravenous line was placed for drug or saline placebo infusion. Participants were also fitted with an investigational in-ear wearable device from Applied Cognition¹⁷ that measured key determinants of glymphatic function, including sleep features (hypnogram and spectral band power) by EEG, heart rate variability (HRV) by photoplethysmography (PPG), cerebrovascular pulse transit time (PTT cereb ) by impedance plethysmography (IPG), and brain parenchymal resistance (R P ) by dynamic electrical impedance spectroscopy.
    Wearable Telemetry Electrocardiography (Ecg) Monitor, supplied by Welch Allyn Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monitoring+by+electrocardiography+ecg+telemetry/wearable+telemetry+electrocardiography++ecg++monitor/pmc06436502-85-1-6
    Average 90 stars, based on 1 article reviews
    wearable telemetry electrocardiography (ecg) monitor - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    diagnostic 12-lead electrocardiography (ecg) telemetry monitoring surveyor  (Mortara Instrument)
    90
    Mortara Instrument diagnostic 12-lead electrocardiography (ecg) telemetry monitoring surveyor
    The Dexmedetomidine Trial was conducted at Stanford University’s Clinical and Translational Research Unit (CTRU), while the ACX-02 Clinical Trial was conducted at both Stanford University’s CTRU and Washington State University’s Sleep and Performance Research Center. Both trials used a cross-over design - treatment followed by placebo - to assess the effect of DEX on the glymphatic clearance of Aβ and tau from the brain to the blood. (A) The Dexmedetomidine Trial enrolled nine participants, of whom eight completed both study visits. (B) The ACX-02 Trial enrolled 22 participants, eight at Stanford University and 14 at Washington State University. Of the eight participants at Stanford, six completed both study visits. At Washington State University, 11 of 14 participants completed both study visits. (C) Illustration of the determinants of glymphatic clearance of Aβ and tau during wake, NREM sleep, DEX and ACX-02 treatment. To capture these physiological determinants, participants were instrumented with <t>ECG</t> telemetry, percutaneous oxygen saturation (SpO₂), nasal cannula for low-flow oxygen and continuous end-tidal CO₂ (EtCO₂) monitoring, and a radial arterial line for continuous blood pressure monitoring and blood sampling (Philips IntelliVue MP50). An intravenous line was placed for drug or saline placebo infusion. Participants were also fitted with an investigational in-ear wearable device from Applied Cognition¹⁷ that measured key determinants of glymphatic function, including sleep features (hypnogram and spectral band power) by EEG, heart rate variability (HRV) by photoplethysmography (PPG), cerebrovascular pulse transit time (PTT cereb ) by impedance plethysmography (IPG), and brain parenchymal resistance (R P ) by dynamic electrical impedance spectroscopy.
    Diagnostic 12 Lead Electrocardiography (Ecg) Telemetry Monitoring Surveyor, supplied by Mortara Instrument, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monitoring+by+electrocardiography+ecg+telemetry/12+lead+ecg/pm22345697-37-71-77
    Average 90 stars, based on 1 article reviews
    diagnostic 12-lead electrocardiography (ecg) telemetry monitoring surveyor - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    The Dexmedetomidine Trial was conducted at Stanford University’s Clinical and Translational Research Unit (CTRU), while the ACX-02 Clinical Trial was conducted at both Stanford University’s CTRU and Washington State University’s Sleep and Performance Research Center. Both trials used a cross-over design - treatment followed by placebo - to assess the effect of DEX on the glymphatic clearance of Aβ and tau from the brain to the blood. (A) The Dexmedetomidine Trial enrolled nine participants, of whom eight completed both study visits. (B) The ACX-02 Trial enrolled 22 participants, eight at Stanford University and 14 at Washington State University. Of the eight participants at Stanford, six completed both study visits. At Washington State University, 11 of 14 participants completed both study visits. (C) Illustration of the determinants of glymphatic clearance of Aβ and tau during wake, NREM sleep, DEX and ACX-02 treatment. To capture these physiological determinants, participants were instrumented with ECG telemetry, percutaneous oxygen saturation (SpO₂), nasal cannula for low-flow oxygen and continuous end-tidal CO₂ (EtCO₂) monitoring, and a radial arterial line for continuous blood pressure monitoring and blood sampling (Philips IntelliVue MP50). An intravenous line was placed for drug or saline placebo infusion. Participants were also fitted with an investigational in-ear wearable device from Applied Cognition¹⁷ that measured key determinants of glymphatic function, including sleep features (hypnogram and spectral band power) by EEG, heart rate variability (HRV) by photoplethysmography (PPG), cerebrovascular pulse transit time (PTT cereb ) by impedance plethysmography (IPG), and brain parenchymal resistance (R P ) by dynamic electrical impedance spectroscopy.

    Journal: medRxiv

    Article Title: Pharmacological enhancement of glymphatic function in humans increases the clearance of Alzheimer’s disease-related proteins

    doi: 10.64898/2026.03.10.26348048

    Figure Lengend Snippet: The Dexmedetomidine Trial was conducted at Stanford University’s Clinical and Translational Research Unit (CTRU), while the ACX-02 Clinical Trial was conducted at both Stanford University’s CTRU and Washington State University’s Sleep and Performance Research Center. Both trials used a cross-over design - treatment followed by placebo - to assess the effect of DEX on the glymphatic clearance of Aβ and tau from the brain to the blood. (A) The Dexmedetomidine Trial enrolled nine participants, of whom eight completed both study visits. (B) The ACX-02 Trial enrolled 22 participants, eight at Stanford University and 14 at Washington State University. Of the eight participants at Stanford, six completed both study visits. At Washington State University, 11 of 14 participants completed both study visits. (C) Illustration of the determinants of glymphatic clearance of Aβ and tau during wake, NREM sleep, DEX and ACX-02 treatment. To capture these physiological determinants, participants were instrumented with ECG telemetry, percutaneous oxygen saturation (SpO₂), nasal cannula for low-flow oxygen and continuous end-tidal CO₂ (EtCO₂) monitoring, and a radial arterial line for continuous blood pressure monitoring and blood sampling (Philips IntelliVue MP50). An intravenous line was placed for drug or saline placebo infusion. Participants were also fitted with an investigational in-ear wearable device from Applied Cognition¹⁷ that measured key determinants of glymphatic function, including sleep features (hypnogram and spectral band power) by EEG, heart rate variability (HRV) by photoplethysmography (PPG), cerebrovascular pulse transit time (PTT cereb ) by impedance plethysmography (IPG), and brain parenchymal resistance (R P ) by dynamic electrical impedance spectroscopy.

    Article Snippet: Participants were instrumented for monitoring by electrocardiography (ECG) telemetry, percutaneous oxygen saturation (SpO 2 ), nasal canula for administration of supplemental oxygen at 2 liters per minute (LPM) and continuous end-tidal CO 2 (EtCO 2 ) monitoring, and a 20 gauge (g) radial arterial catheter at the wrist for continuous systemic blood pressure measurement and blood sampling (Philips IntelliVue MP50 Patient Monitor).

    Techniques: Clinical Proteomics, Sampling, Saline, Impedance Spectroscopy